A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1b open-label study designed to characterize the safety, tolerability,
and preliminary anti-tumor activity of WU-NK-101 in combination with cetuximab in patients
with advanced and/or metastatic CRC (Cohort 1), and in patients with advanced and/or
metastatic SCCHN (Cohort 2). The overall study will be comprised of two phases, a Dose
Escalation Phase, and a Cohort Expansion Phase.